摘要
为探讨13 1I治疗Graves′病甲亢的疗效及影响疗效的因素 ,将13 1I治疗后 1年的患者 ,根据随访结果分为早发甲状腺功能减低(早发甲减 )组、无甲减组 ,各随机抽取 4 6例、6 0例 ,采用SAS统计软件分析甲状腺重量、最高摄碘率、吸收剂量、甲状腺球蛋白抗体(TGA)和甲状腺微粒体抗体 (TMA)与早发甲减的关系。结果发现 ,两组间甲状腺重量差异有显著性意义 (P =0 0 10 6 ) ,两组间的吸收剂量差异无显著性意义 (P =0 4 4 2 0 ) ,但最高摄碘率差异有显著性意义 (t=2 172 5 ,P =0 0 32 1) ;两组间的TGA、TMA阳性数差异无显著性意义(χ2 =1 15 6 ,P=0 2 82 )。提示早发甲减与甲状腺重量、最高摄碘率有关 ,与计算剂量时所给的吸收剂量。
This retrospective study was designed to analyze the early therapeutic outcome of radioiodine therapy in patients with Graves'disease. According to the follow up result after one year treatment, patients were divided into two groups on the basis of whether there was signs of hypothyroidism. 46 patients with hypothyroidism, 60 patients without hypothyroidism were selected randomly. The SAS software was used to assess the outcome of early hypothyroidism and the thyroid weight, the peak of 131 I uptake, absorption value by per gram of thyroid tissue, thyroglobulin autoantibody (TGA), and thyroid microsome autoantibody (TMA) levels. Rank sum test, t test and χ 2 test were used to compare the variable parameters between the two groups. Thyroid weight ( P =0 0106) and the peak of 131 I uptake ( t =2 1725, P =0 0321) between two groups had significant difference. The absorption value of the thyroid tissue ( P =0 4420), thyroid autoantibody (χ 2 =1 156, P =0 282) had no significant difference between two groups. Patients with smaller gland weight and lower 131 I uptake had an inclination to have early hypothyroidism. Absorption value by per gram of thyroid, TGA and TMA levels had no influence on the outcome of 131 I treatment
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2003年第2期180-181,共2页
Medical Journal of Chinese People's Liberation Army
